BELLUS Health Inc. (BLU)
| Market Cap | 270.05M |
| Revenue (ttm) | 12,030 |
| Net Income (ttm) | -28.14M |
| Shares Out | 60.44M |
| EPS (ttm) | -0.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $3.66 |
| Previous Close | $3.46 |
| Change ($) | 0.20 |
| Change (%) | 5.78% |
| Day's Open | 3.49 |
| Day's Range | 3.47 - 3.67 |
| Day's Volume | 255,463 |
| 52-Week Range | 2.14 - 12.02 |
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), announces that it has entered today into an agreement (the “Sales Agreement”) with ...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After establishing a holding in Bellus Health Inc. (NASDAQ:BLU) during the second quarter, billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 A...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...
LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Healt...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...
Bellus (BLU) delivered earnings and revenue surprises of 26.32% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tr...
Bellus (BLU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The economy has been tumultuous, but technical analysis helps us see through the static and zero in on the best penny stock opportunities.
San Francisco, California--(Newsfile Corp. - July 13, 2020) - Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible...
NEW YORK, July 10, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BELLUS Health Inc. ("BELLUS" or ...
San Francisco, California--(Newsfile Corp. - July 8, 2020) - Hagens Berman urges investors in BELLUS Health Inc. (NASDAQ: BLU) to submit their losses now. The firm is investigating possible ...
Canadian biopharma BELLUS Health Inc (NASDAQ: BLU) was losing about three-fourths of its value in Monday's trading session.
Bellus (BLU) delivered earnings and revenue surprises of 0.00% and -60.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor in BELLUS Health.
Bellus (BLU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About BLU
BELLUS Health, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.
| Industry Biotechnology | Founded 1993 |
| CEO Roberto Bellini | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol BLU |
Financial Performance
In 2019, BELLUS Health's revenue was 35,000, a change of 0.00% compared to the previous year's 35,000. Losses were -34.47 million, 279.4% more than in 2018.